Kaleido Biosciences Inc

Kaleido Biosciences, Inc. is a clinical-stage healthcare company, which engages in the provision of healthcare services. It focuses on leveraging the microbiome organ to treat disease and improve human health. The firm offers microbiome metabolic therapies (MMT), which are designed to modulate the metabolic output and profile of the microbiome by driving the function and composition of the organ's existing microbes. The company was founded by Geoffrey von Maltzahn and Noubar B. Afeyan on January 27, 2015 and is headquartered in Lexington, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Clarus Therapeutics Holdings

Powerbridge Technologies Co Ltd

Check these three penny stocks out as Musk tries to buy TWTR The post Best Penny Stocks to Buy? 3 to Watch as Musk Offers $43B for TWTR appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Buy? 3 to Watch as Musk Offers $43B for TWTR

Kaleido Biosciences (KLDO) stock is soaring on Wednesday but anyone considering a stake in the company will want to keep an eye on April 28. The post Dear KLDO Stock Fans, Mark Your Calendars for April 28 appeared first on InvestorPlace.

Dear KLDO Stock Fans, Mark Your Calendars for April 28

Agile Therapeutics

Antares Pharma

Here's what you need to know about trading penny stocks on April 13th The post Best Penny Stocks to Buy? 3 to Watch as ATRS Stock Explodes  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Buy? 3 to Watch as ATRS Stock Explodes

Kaleido Biosciences Inc (NASDAQ: KLDO) has delivered formal notice to voluntarily delist its common stock from NASDAQ as the Company will stop all operations. The Company expects to file a Form 25 with the Securities and Exchange Commission by April 18 to effect the voluntary delisting.

Kaleido Biosciences Shares Plunging To 52-Week Low, Read Why

Kaleido Biosciences, Inc. (KLDO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kaleido Biosciences, Inc. (KLDO) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Kaleido Biosciences, Inc. (KLDO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Here's Why Kaleido Biosciences, Inc. (KLDO) is Poised for a Turnaround After Losing 33.2% in 4 Weeks

LEXINGTON, Mass., Jan. 21, 2022 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory conditions and diseases by selectively targeting the resident microbiome to restore gut-immune homeostasis, today announced that the topline data obtained with KB295, a novel Microbiome Metabolic Therapy (MMT™), in mild-to-moderate ulcerative colitis (UC), will be presented virtually at the 2022 Crohn's and Colitis Congress.

Kaleido Biosciences to Present Updated Data of KB295 In Ulcerative Colitis at the 2022 Crohn's and Colitis Congress

Kaleido Biosciences, Inc. (KLDO) recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom.

Kaleido Biosciences, Inc. (KLDO) Sees Hammer Chart Pattern: Time to Buy?

LEXINGTON, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory conditions and diseases by selectively targeting the resident microbiome to restore gut-immune homeostasis, today announced the extension and expansion of its research collaboration with Janssen Biotech, Inc. (“Janssen”). The collaboration is designed to explore the potential for Microbiome Metabolic Therapies (MMT™) to prevent childhood-onset of atopic, immune and metabolic conditions by promoting healthy function of the gut microbiome.

Kaleido Biosciences Announces Expansion of Collaboration with Janssen to Explore Potential of Microbiome Metabolic Therapies (MMT™) to Prevent Childhood-Onset of Atopic, Immune and Metabolic Conditions

LEXINGTON, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory conditions and diseases by selectively targeting the resident microbiome to restore gut-immune homeostasis, today announced the appointment of Alison Long, M.B.B.Ch., Ph.D., to its leadership team as Chief Medical Officer, effective December 15, 2021. In her new role, Dr. Long will be responsible for leading the development of Kaleido's ongoing and future clinical programs, including the development of KB295 and KB109 in ulcerative colitis and chronic obstructive pulmonary disease, respectively.

Kaleido Biosciences to Appoint Dr. Alison Long as Chief Medical Officer

Kaleido Biosciences, Inc. (KLDO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Here's Why Kaleido Biosciences, Inc. (KLDO) Is a Great 'Buy the Bottom' Stock Now

Kaleido Biosciences, Inc. (KLDO) delivered earnings and revenue surprises of 1.82% and -58.40%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Kaleido Biosciences, Inc. (KLDO) Reports Q3 Loss, Misses Revenue Estimates

--Achieved primary objective of safety and tolerability in clinical study evaluating KB295 in mild-to-moderate ulcerative colitis; meaningful reduction observed in key biomarkers correlated with disease activity and inflammation-- --Remain on track to initiate Phase 2 clinical trials of KB109 in COPD and KB295 in UC in first half 2022--

Kaleido Biosciences Reports Third Quarter 2021 Financial Results

Kaleido Biosciences, Inc. (KLDO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Down 23.6% in 4 Weeks, Here's Why Kaleido Biosciences, Inc. (KLDO) Looks Ripe for a Turnaround

Kaleido Biosciences, Inc. (KLDO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kaleido Biosciences, Inc. (KLDO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

LEXINGTON, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory conditions and diseases by selectively targeting the resident microbiome to restore gut-immune homeostasis, today announced that CEO Dan Menichella will present a company overview at the Jefferies Virtual Next Generation IBD Therapeutics Summit at 1:45PM ET on Tuesday, October 19.

Kaleido Biosciences to Participate in the Jefferies Virtual Next Generation IBD Therapeutics Summit

Kaleido Biosciences Inc (NASDAQ: KLDO) announced topline data from the non-IND/CTA clinical study evaluating KB295, a novel Microbiome Metabolic Therapy (MMT), in mild-to-moderate ulcerative colitis (UC).  The study achieved the primary objective of safety and tolerability with no product-emergent serious adverse events reported.

Why Did Kaleido Shares Plunge 10% On Tuesday?

Arbutus Biopharma

Adverum Biotechnologies

MannKind

Trevena

Will upcoming events mean big things for these penny stocks? The post 5 Penny Stocks To Watch This Week With Potential Biotech Catalysts appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Penny Stocks To Watch This Week With Potential Biotech Catalysts

Latest data and clinical development plans for KB295 in ulcerative colitis (UC) to be presented

Kaleido Biosciences to Host Virtual R&D Presentation to Discuss Clinical Data and Pipeline Advancement on October 5, 2021

The FDA has issued a warning letter to Kaleido Biosciences Inc (NASDAQ: KLDO), blasting its “failure to submit Investigational New Drug applications for a clinical trial with an investigational new drug” that falls under section 505. Related Content:   Kaleido Reports Positive KB109 Data In COVID-19 Study.

FDA Questions Kaleido Biosciences 'Non-IND' COVID-19 Trial

LEXINGTON, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced that CEO Dan Menichella will participate in a fireside chat at the Morgan Stanley 19th Annual Virtual Global Healthcare Conference at 2:45PM ET on Thursday, September 9.

Kaleido Biosciences to Participate in the Morgan Stanley 19th Annual Virtual Global Healthcare Conference

Kaleido Biosciences, Inc. (KLDO) delivered earnings and revenue surprises of 5.08% and -15.60%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Kaleido Biosciences, Inc. (KLDO) Reports Q2 Loss, Lags Revenue Estimates

--On track to report topline data from a clinical study of KB295 in patients with mild-to-moderate ulcerative colitis by end of third quarter-- --Kaleido and the COPD Foundation to collaborate on the development of KB109 in patients with COPD; plan to initiate Phase 2 clinical study in first quarter 2022--

Kaleido Biosciences Reports Second Quarter 2021 Financial Results

On track to initiate Phase 2 trial in the first quarter of 2022 On track to initiate Phase 2 trial in the first quarter of 2022

Kaleido Biosciences and the COPD Foundation Announce a Strategic Collaboration to Advance KB109 into Phase 2 Clinical Trial

Current Director Theo Melas-Kyriazi appointed Chairperson of the Board of Directors Current Director Theo Melas-Kyriazi appointed Chairperson of the Board of Directors

News for Kaleido Biosciences Inc Stock (KLDO)